View Financial HealthBioNTech 배당 및 자사주 매입배당 기준 점검 0/6BioNTech 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBioNTech SE And Duality Biologics Demonstrate Clinically Meaningful Efficacy of Trastuzumab Pamirtecan In Patients With HER2-Expressing Recurrent Endometrial CancerApr 11BioNTech SE, Annual General Meeting, May 15, 2026Apr 05BioNTech SE to Report Q2, 2026 Results on Aug 04, 2026Mar 28+ 2 more updatesBioNTech Se Presents Clinical Data Updates for Late-Stage Lung Cancer PortfolioMar 25Özlem Türeci to Depart as Chief Medical Officer of BioNTech SE by the End of the YearMar 11+ 1 more updateBioNTech SE Provides Financial Guidance for the Year 2026Mar 10BioNTech SE Announces Appointment of Kylie Jimenez to the Management Board as Chief People Officer, Effective March 1, 2026Jan 28Biontech Provides Oncology Areas of Focus for 2026Jan 13BioNTech SE (NasdaqGS:BNTX) completed the acquisition of CureVac N.V. (NasdaqGM:CVAC) from dievini Hopp BioTech holding GmbH & Co. KG, KfW and others.Dec 18Pfizer Reportedly Looks to Sell Stake in Pandemic Vaccine Partner BioNTechNov 13BioNTech SE to Report Q4, 2025 Results on Mar 10, 2026Nov 03+ 1 more updateBioNTech SE to Report Q3, 2025 Results on Nov 03, 2025Oct 27Arbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit UpdateSep 12Oncoc4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation Ctla-4 Antibody Gotistobart Monotherapy Being Co-Developed with Biontech in Nsclc At the Iaslc 2025 World Conference on Lung CancerSep 08+ 1 more updatePfizer Canada ULC and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 VaccineAug 19Gsk Updates on Mrna Patent Settlement with Curevac and BiontechAug 08BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25BioNTech SE to Report Q2, 2025 Results on Aug 04, 2025Jul 21BioNTech SE Announces Ryan Richardson Step Down as Chief Strategy Officer, Effective September 30, 2025Jul 17BioNTech SE to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual MeetingMay 30BioNTech SE Confirms Earnings Guidance for the Year 2025May 06BioNTech SE Announces Chief Financial Officer ChangesMay 05BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025Apr 24BioNTech SE to Report Q1, 2025 Results on May 05, 2025Apr 22BioNTech SE, Annual General Meeting, May 16, 2025Mar 11BioNTech SE Provides Earnings Guidance for the Financial Year 2025Mar 10BioNTech SE to Report Q4, 2024 Results on Mar 10, 2025Feb 24BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Biotheus Inc.Feb 05BioNTech SE and BioNTech RNA Pharmaceuticals GmbH Enter Settlement Agreement with University of PennsylvaniaDec 28+ 1 more updateBioNTech SE And its Partner OncoC4 Inc. Continue Enrollment In Phase 3 Trial For BNT316/ONC-392 After FDA Lifts Partial HoldDec 14Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024Dec 06BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.Nov 15Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023) Nov 04BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024Oct 21BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)Oct 18Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European UnionSep 20New major risk - Revenue and earnings growth Sep 16Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 VaccineAug 23Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of AgeAug 16University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbHAug 07BioNTech SE Reiterates Earnings Guidance for the Year 2024Aug 06Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023) Aug 06BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024Jul 22New minor risk - Earnings quality May 30New major risk - Revenue and earnings growth May 23BioNTech SE Reiterates Revenue Guidance for the Full Year 2024May 08First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023) May 06BioNTech SE to Report Q1, 2024 Results on May 06, 2024Apr 23Now 20% undervalued after recent price drop Apr 03New major risk - Revenue and earnings growth Mar 22Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022) Mar 21BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024Mar 20BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial OfficerMar 08New minor risk - Shareholder dilution Feb 19BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305Feb 01BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast CancerJan 23Robbins LLP Informs Investors of Class Action Filed Against BioNTech SEJan 17BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial CancerDec 22BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.Nov 09+ 1 more updateBioNTech SE to Report Q4, 2023 Results on Mar 20, 2024Nov 07Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022) Nov 07Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19Oct 28BioNTech SE, Annual General Meeting, May 17, 2024Oct 21BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer IndicationOct 20Investor sentiment deteriorates as stock falls 15% Oct 18New minor risk - Share price stability Oct 05Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in GermanyOct 01Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 VaccineSep 29Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 VaccineSep 12Investor sentiment improves as stock rises 18% Aug 22BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023Aug 15BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023Aug 08Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022) Aug 08BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.Aug 01BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023Jul 25BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLCJun 30BioNTech SE Provides Revenue Guidance for the Full Year 2023May 10Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021) Mar 28Investor sentiment deteriorated over the past week Dec 29Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021) Nov 08지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 22UA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 22UA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BioNTech 배당 수익률 vs 시장22UA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (22UA)n/a시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.3%분석가 예측 (22UA) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 22UA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 22UA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 22UA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 22UA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 19:59종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioNTech SE는 34명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Zhiqiang ShuBerenbergSamuel EnglandBerenbergHarry GillisBerenberg31명의 분석가 더 보기
BioNTech SE And Duality Biologics Demonstrate Clinically Meaningful Efficacy of Trastuzumab Pamirtecan In Patients With HER2-Expressing Recurrent Endometrial CancerApr 11
Özlem Türeci to Depart as Chief Medical Officer of BioNTech SE by the End of the YearMar 11+ 1 more update
BioNTech SE Announces Appointment of Kylie Jimenez to the Management Board as Chief People Officer, Effective March 1, 2026Jan 28
BioNTech SE (NasdaqGS:BNTX) completed the acquisition of CureVac N.V. (NasdaqGM:CVAC) from dievini Hopp BioTech holding GmbH & Co. KG, KfW and others.Dec 18
Oncoc4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation Ctla-4 Antibody Gotistobart Monotherapy Being Co-Developed with Biontech in Nsclc At the Iaslc 2025 World Conference on Lung CancerSep 08+ 1 more update
Pfizer Canada ULC and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 VaccineAug 19
BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25
BioNTech SE Announces Ryan Richardson Step Down as Chief Strategy Officer, Effective September 30, 2025Jul 17
BioNTech SE to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual MeetingMay 30
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025Apr 24
BioNTech SE and BioNTech RNA Pharmaceuticals GmbH Enter Settlement Agreement with University of PennsylvaniaDec 28+ 1 more update
BioNTech SE And its Partner OncoC4 Inc. Continue Enrollment In Phase 3 Trial For BNT316/ONC-392 After FDA Lifts Partial HoldDec 14
Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024Dec 06
BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)Oct 18
Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European UnionSep 20
Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 VaccineAug 23
Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of AgeAug 16
University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbHAug 07
BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024Mar 20
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305Feb 01
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast CancerJan 23
BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial CancerDec 22
Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19Oct 28
BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer IndicationOct 20
Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in GermanyOct 01
Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 VaccineSep 29
BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLCJun 30